Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX Pharmacogenetic Dose Adjusted in Elderly Patients With Metastatic Pancreatic Adenocarcinoma
NCT02143219Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jul 2014
- Primary completion
- Nov 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by Institut Cancérologique de l'Ouest. Started Jul 2014; status: completed.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02143219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143219.